Extension of the Brinkman-Rice picture and the Mott transition

In order to explain the metal-Mott-insulator transition, the Brinkman-Rice (BR) picture is extended. In the case of less than one as well as one electron per atom, the on-site Coulomb repulsion is given by U={kappa}{rho}^2U_c by averaging the electron charge per atom over all atomic sites, where {kappa} is the correlation strength of U, {rho} is the band filling factor, and U_c is the critical on-site Coulomb energy. The effective mass of a quasiparticle is found to be m*/m=1/{1-{kappa}^2{rho}^4} for 0<{kappa}{rho}^2<1 and seems to follow the heat capacity data of Sr_{1-x}La_xTiO_3 and YBa_2Cu_3O_{7-delta} at {kappa}=1 and 0<{kappa}{rho}^2<1. The Mott transition of the first order occurs at {kappa}{rho}^2=1 and a band-type metal-insulator transition takes place at {kappa}{rho}^2=0. This Mott transition is compared with that in the d=infinity Hubbard model. The effective mass for 2D-DOS instead of the vHs can be used for the mechanism of high T_c superconductivity.Comment: RevTex, Physica C, Vol. 341-348, 259-260 (2000

In Vitro Chemosensitivity Using the Histoculture Drug Response Assay in Human Epithelial Ovarian Cancer

The choice of chemotherapeutic drugs to treat patients with epithelial ovarian cancer has not depended on individual patient characteristics. We have investigated the correlation between in vitro chemosensitivity, as determined by the histoculture drug response assay (HDRA), and clinical responses in epithelial ovarian cancer. Fresh tissue samples were obtained from 79 patients with epithelial ovarian cancer. The sensitivity of these samples to 11 chemotherapeutic agents was tested using the HDRA method according to established methods, and we analyzed the results retrospectively. HDRA showed that they were more chemosensitive to carboplatin, topotecan and belotecan, with inhibition rates of 49.2%, 44.7%, and 39.7%, respectively, than to cisplatin, the traditional drug of choice in epithelial ovarian cancer. Among the 37 patients with FIGO stage Ⅲ/Ⅳ serous adenocarcinoma who were receiving carboplatin combined with paclitaxel, those with carboplatin-sensitive samples on HDRA had a significantly longer median disease-free interval than patients with carboplatin- resistant samples (23.2 vs. 13.8 months, p＜0.05), but median overall survival did not differ significantly (60.4 vs. 37.3 months, p＝0.621). In conclusion, this study indicates that HDRA could provide useful information for designing individual treatment strategies in patients with epithelial ovarian cancer